Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
Kymera Therapeutics presented Phase 1 data for its oral STAT6 degrader KT-621 in healthy Japanese adults at the Japanese Dermatological Association Annual Meeting. The study showed rapid, sustained STAT6 degradation of at least 98% at Day 7 across both dose levels, with a favorable safety profile consistent with previous non-Japanese studies.
Key figures
- Drug Name
- KT-621
- Phase Of Trial
- Phase 1
- Study population
- 24 healthy Japanese adults
- Stat6 degradation
- >=98%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.